Zealand Pharma Reports 2025 Financials, Highlights Roche Partnership and Pipeline Milestones
Event summary
- Zealand Pharma reported DKK 9.2 billion in revenue for 2025, up from DKK 63 million in 2024, driven by a transformative partnership with Roche for petrelintide.
- The company expects potential milestone payments from Roche totaling USD 700 million in 2026, including a USD 575 million development milestone and a USD 125 million anniversary payment.
- Key clinical milestones anticipated in 2026 include Phase 2 petrelintide data from the ZUPREME program and Phase 3 survodutide data from the SYNCHRONIZETM obesity program.
- Zealand Pharma plans to establish a research site in Boston in 2026 to expand its pharmacological reach and integrate AI-driven drug discovery.
The big picture
Zealand Pharma's 2025 financial results highlight the strategic shift towards obesity and metabolic health, bolstered by high-profile partnerships with Roche and Boehringer Ingelheim. The company's ambitious Metabolic Frontier 2030 strategy aims to position it as a leader in the rapidly evolving metabolic health market, leveraging AI-driven drug discovery and advanced automation to fuel its pipeline. The significant revenue growth and potential milestone payments underscore the scale of its transformation from a clinical-stage biotech to a generational player in metabolic health.
What we're watching
- Clinical Trial Outcomes
- The pace at which Zealand Pharma reports Phase 2 petrelintide data and Phase 3 survodutide data will determine the timeline for potential regulatory submissions.
- Partnership Execution
- Whether Zealand Pharma can sustain the momentum from its Roche partnership and deliver on the expected milestone payments.
- Research Expansion
- How the establishment of a Boston research site will impact Zealand Pharma's ability to accelerate drug discovery and development.
Related topics